Immunocore Holdings plc 8-K

What Happened
Immunocore Holdings plc filed an 8-K reporting the results of its Annual General Meeting of Shareholders held May 27, 2026. Ten resolutions were voted on and passed on a poll, including reappointments of directors Siddharth Kaul and William Pao, M.D., Ph.D., reappointment of Kristine Peterson, ratification and reappointment of Deloitte LLP as auditors, and advisory approval of executive compensation (say-on-pay). The company’s definitive proxy statement was filed April 16, 2026.

Key Details

• All ten resolutions were approved at the AGM on May 27, 2026.
• Director reappointments:
  • Siddharth Kaul: 38,033,664 for / 261,819 against (≈0.7% against).
  • William Pao, M.D., Ph.D.: 38,040,755 for / 254,852 against (≈0.67% against).
  • Kristine Peterson: 29,537,800 for / 8,744,383 against (≈22.8% against).
• Advisory vote on named executive officers’ compensation: 29,682,169 for / 8,600,029 against (≈22.5% against).
• Ratification/reappointment of auditors (Deloitte LLP) was nearly unanimous: 38,294,666 for / 984 against.
• Directors’ remuneration report received significant opposition: 29,504,692 for / 8,713,573 against (≈22.8% against).

Why It Matters
These results show broad support for the board and auditors overall, but notable minority opposition (about 22–23%) on governance and pay-related items — including one director reappointment, the advisory say-on-pay vote, and the directors’ remuneration report. For retail investors, sustained vote opposition at this level is a clear, measurable signal of shareholder concern about executive compensation or governance practices and could prompt further disclosure or shareholder engagement in future filings or meetings.